Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Multicenter Clinical Study on Robotic-Assisted Surgical Management of Posterior Cruciate Ligament Tibial Avulsion Fractures

4 maggio 2026 aggiornato da: YujiakuoTHU, Beijing Tsinghua Chang Gung Hospital
The primary objective of this clinical trial is to evaluate the efficacy of robotic-assisted surgery in the management of posterior cruciate ligament (PCL) avulsion fractures involving the tibial insertion site of the cruciate ligament. Specifically, the study seeks to determine: (1) whether robotic-assisted surgery yields superior anatomical reduction accuracy-particularly in restoring the native position of the tibial avulsion fragment-compared with conventional open reduction and internal fixation (ORIF); and (2) whether such improved precision translates into enhanced long-term functional recovery of the knee joint.

Panoramica dello studio

Descrizione dettagliata

Patients diagnosed with posterior cruciate ligament (PCL) tibial avulsion fractures-confirmed according to established radiographic and clinical diagnostic criteria-were prospectively enrolled from three geographically distinct regional medical centers. Prior to enrollment, all participants received comprehensive oral and written information detailing the study's objectives, methodology, potential risks and benefits, and the two comparative surgical interventions: robotic-assisted fixation and conventional open reduction and internal fixation (ORIF). Written informed consent was obtained from each participant following a mandatory reflection period and prior to randomization or any study-related procedures. All enrolled patients underwent standardized preoperative imaging, including anteroposterior and lateral radiographs of the knee, computed tomography (CT), and magnetic resonance imaging (MRI). Imaging interpretation was performed independently by two board-certified musculoskeletal radiologists blinded to group allocation; consensus adjudication resolved discrepancies. Radiological assessment confirmed diagnosis, classified fracture morphology using the Meyers-McKeever classification , and verified adherence to prespecified inclusion and exclusion criteria. Participants were then allocated in a 1:1 ratio to either the robotic-assisted surgery group (intervention group) or the ORIF group (control group) via centralized, stratified randomization-stratified by ageand fracture type . Baseline demographic, clinical, and functional assessments-including physical examination and validated patient-reported outcome measures (e.g., IKDC subjective score)-were completed preoperatively. All surgical procedures were performed by senior orthopedic surgeons with subspecialty expertise in knee trauma, either directly or under their immediate supervision, to ensure procedural fidelity and minimize interoperator variability. Primary and secondary outcomes were assessed at prespecified time points using objective, validated, and reproducible metrics. Radiographic evaluation of reduction accuracy entailed measurement of maximal sagittal displacement of the avulsed fragment on postoperative CT scans acquired within 72 ± 24 hours after surgery. The IKDC subjective score was collected at 24 weeks (±2 weeks) and 12 months (±1 month) postoperatively. Fracture union was determined radiologically using CT criteria and knee range of motion (ROM) was measured using a standard goniometer at 12 weeks (±1 week) and 24 weeks (±2 weeks). Intraoperative process metrics-including operative duration, intraoperative fluoroscopic exposure count, estimated blood loss (measured gravimetrically and volumetrically), and incidence of adverse events (e.g., surgical site infection, neurovascular injury, implant-related complications, or unplanned reoperation)-were systematically documented and compared between groups. Randomization was implemented using a computer-generated, permuted-block randomization sequence managed centrally and stratified as noted above. Statistical analyses adhered to a prespecified analysis plan: normality of continuous variables was assessed using the Shapiro-Wilk test; normally distributed data are presented as mean ± standard deviation and compared using independent-samples t-tests; non-normally distributed data are reported as median (interquartile range) and analyzed using the Mann-Whitney U test. Missing data were addressed via multiple imputation , followed by sensitivity analyses using complete-case and worst-case scenarios. Categorical variables are expressed as frequency (percentage) and compared using the chi-square test or Fisher's exact test, as appropriate.

Tipo di studio

Interventistico

Iscrizione (Stimato)

22

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 102218
        • Beijing Tsinghua Changgung Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Age ≥ 18 years

    • Acute closed tibial avulsion fracture, with surgery performed within 3 weeks of injury ③ Radiographically confirmed Meyers-McKeever classification Type II or III fracture ④ Absence of absolute contraindications to surgical intervention ⑤ Provision of voluntary, written informed consent prior to enrollment

Exclusion Criteria:

  • Pathological fractures or complex ipsilateral injuries, including concomitant fractures at other anatomical sites.

    • Prior ipsilateral knee joint surgery. ③. Significant vascular or neurological compromise.

      • Acute meniscal tears, acute anterior cruciate ligament (ACL) ruptures, or acute injuries to the medial or lateral collateral ligaments.

        • Compromised local soft tissue integrity, including open fractures. ⑥. Withdrawal from the study or loss to follow-up despite having provided written informed consent.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Experimental group
Perform surgical robot-assisted arthroscopic surgery
Experimental group: Robot-assisted arthroscopic surgery
Altro: Control group
Traditional posterior incision reduction and internal fixation surgery is performed
Control group: incisional reduction and internal fixation surgery

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
the quality of surgical reduction
Lasso di tempo: 72 hours (±24 hours) after the surgery
In the CT scan images obtained approximately 72 hours (±24 hours) after the surgery, the maximum distance between the fracture fragments was measured on the sagittal plane.
72 hours (±24 hours) after the surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Yu Jia-kuo, Beijing Tsinghua Changgeng Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

10 maggio 2026

Completamento primario (Stimato)

31 dicembre 2030

Completamento dello studio (Stimato)

31 dicembre 2030

Date di iscrizione allo studio

Primo inviato

12 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

4 maggio 2026

Primo Inserito (Effettivo)

8 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Descrizione del piano IPD

The original dataset will be made available to the collaborating research team no later than 12 months following the completion of the clinical trial. Subsequently, de-identified data will be shared via a secure, encrypted transmission protocol. Any use of the data is strictly contingent upon prior written approval from the principal investigator and formal authorization by the institutional ethics review board, and shall be limited exclusively to peer-reviewed scientific research activities.

Periodo di condivisione IPD

The original data will be transferred to the collaborating research team within 12 months following the completion of the clinical trial and will remain accessible to them for a period of two years.

Criteri di accesso alla condivisione IPD

Within a defined timeframe following the conclusion of the trial, the collaborative research team may access the data repository and share de-identified data-including treatment records, follow-up assessments, and laboratory results-via secure data transmission methods. Any use of such data requires prior written agreement from the Principal Investigator and formal approval from the relevant Ethics Committee, and is strictly limited to scientific research purposes.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Surgical robot-assisted arthroscopic surgery

Sottoscrivi